Identification and structural characterization of in vivo metabolites of ketorolac using liquid chromatography electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS)

被引:11
作者
Raju, B. [1 ]
Ramesh, M. [1 ]
Borkar, Roshan M. [1 ]
Padiya, Raju [2 ]
Banerjee, Sanjay K. [2 ]
Srinivas, R. [1 ]
机构
[1] Indian Inst Chem Technol, Natl Ctr Mass Spectrometry, Hyderabad 500007, Andhra Pradesh, India
[2] Indian Inst Chem Technol, Div Pharmacol, Discovery Lab, Hyderabad 500007, Andhra Pradesh, India
来源
JOURNAL OF MASS SPECTROMETRY | 2012年 / 47卷 / 07期
关键词
ketorolac; LC; ESI-MS; MS; metabolites; accurate mass measurements; online H; D exchange experiments; LC-MS; PLASMA; PHARMACOKINETICS; COMBINATION; ENANTIOMERS;
D O I
10.1002/jms.3043
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In vivo metabolites of ketorolac (KTC) have been identified and characterized by using liquid chromatography positive ion electrospray ionization high resolution tandem mass spectrometry (LC/ESI-HR-MS/MS) in combination with online hydrogen/deuterium exchange (HDX) experiments. To identify in vivo metabolites, blood urine and feces samples were collected after oral administration of KTC to SpragueDawley rats. The samples were prepared using an optimized sample preparation approach involving protein precipitation and freeze liquid separation followed by solid-phase extraction and then subjected to LC/HR-MS/MS analysis. A total of 12 metabolites have been identified in urine samples including hydroxy and glucuronide metabolites, which are also observed in plasma samples. In feces, only O-sulfate metabolite and unchanged KTC are observed. The structures of metabolites were elucidated using LC-MS/MS and MSn experiments combined with accurate mass measurements. Online HDX experiments have been used to support the structural characterization of drug metabolites. The main phase I metabolites of KTC are hydroxylated and decarbonylated metabolites, which undergo subsequent phase II glucuronidation pathways. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:919 / 931
页数:13
相关论文
共 23 条
[1]   Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes [J].
Beuck, S. ;
Schaenzer, W. ;
Thevis, M. .
JOURNAL OF MASS SPECTROMETRY, 2011, 46 (02) :112-130
[2]   Structural characterization of in vitro rat liver microsomal metabolites of antihistamine desloratadine using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange HR-LC/MS [J].
Chen, Guodong ;
Daaro, Ibrahim ;
Pramanik, Birendra N. ;
Piwinski, John J. .
JOURNAL OF MASS SPECTROMETRY, 2009, 44 (02) :203-213
[3]   THE DIRECT DETERMINATION OF THE ENANTIOMERS OF KETOROLAC AND PARAHYDROXYKETOROLAC IN PLASMA AND URINE USING ENANTIOSELECTIVE LIQUID-CHROMATOGRAPHY ON A HUMAN SERUM ALBUMIN-BASED CHIRAL STATIONARY-PHASE [J].
DIAZPEREZ, MJ ;
CHEN, JC ;
AUBRY, AF ;
WAINER, IW .
CHIRALITY, 1994, 6 (04) :283-289
[4]  
ESCOUSSE A, 1995, EUR J CLIN PHARMACOL, V48, P309
[5]   Ketorolac - A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management [J].
Gillis, JC ;
Brogden, RN .
DRUGS, 1997, 53 (01) :139-188
[6]   DETECTION OF KETOROLAC ENANTIOMERS IN HUMAN PLASMA USING ENANTIOSELECTIVE LIQUID-CHROMATOGRAPHY [J].
JONES, DJ ;
BJORKSTEN, AR .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 661 (01) :165-167
[7]  
Jun D., 1989, PHARM RES, V6, P62
[8]   Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children [J].
Kauffman, RE ;
Lieh-Lai, MW ;
Uy, HG ;
Aravind, MK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (04) :382-388
[9]   In electrospray ionization source hydrogen/deuterium exchange LC-MS and LC-MS/MS for characterization of metabolites [J].
Lam, W ;
Ramanathan, R .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2002, 13 (04) :345-353
[10]   Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches [J].
Liu, DQ ;
Hop, CECA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 37 (01) :1-18